Shorter Scope Interval Supported for Better CA Stage at Diagnosis

This article originally appeared here.
Share this content:
Shorter Scope Interval Supported for Better CA Stage at Diagnosis
Shorter Scope Interval Supported for Better CA Stage at Diagnosis

(HealthDay News) – There is a significant benefit in the cancer stage at diagnosis for patients who undergo endoscopy screening, with similar benefits seen for intervals of 1, 2, and 3 years, according to a study published online July 16 in Cancer.

Ji Hyung Nam, MD, from the National Cancer Center in Goyang, South Korea, and colleagues examined the association between the interval between upper gastrointestinal endoscopies and the gastric cancer stage at diagnosis in 2,485 patients from a geographical region of high prevalence. Patients were stratified based on the interval between the endoscopy diagnosing gastric cancer and the endoscopy preceding it.

The researchers found that an increase in interval length correlated with a 23% increase in the risk of higher cancer stage at diagnosis. The odds ratio of having a higher stage of cancer decreased gradually, from 0.53 in the more-than-5-year interval group to 0.31 in the 1-year interval group, compared to those never screened. Compared with the 1-year interval group, there was no increase in the risk of advanced gastric cancer in the 2- and 3-year groups, but the risk was increased in the 4- and 5-year groups. For patients with a family history, those in the 3-year interval group, compared with the 1-year interval group, had an increased risk of higher stage at diagnosis.

"A significant benefit in cancer stage at diagnosis was observed in all interval groups compared to never-screened," the authors write. "Endoscopy intervals of 3 years or less showed similar benefits, but family members of gastric cancer patients may benefit from intervals of under 3 years."

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs